je.st
news
Lilly profit beats analyst estimates as Cymbalta sales climb
2013-01-29 16:01:20| Biotech - Topix.net
Eli Lilly and Co.'s fourth quarter earnings slipped 4 percent as generic competition continued to eat away at sales of its former best-seller, the antipsychotic Zyprexa, but the drugmaker cut expenses again and growth from other products helped it beat analyst expectations.
Tags: sales
profit
estimates
analyst
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||